OLMA
VENTE TOTALE: 25 000 titres (~291 162,50 $ US)
- Insiders
- Harmon Cyrus
- Total bought
- —
- Total sold
- $291,162
- Last activity
- 2026-07-24
- Last synced
-
2026-07-29 21:03:34
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-07-29
OLMA is a pre-revenue biotech with severe fundamental distress (score: 15), zero commercial activity, and persistent cash burn, making its strong liquidity (score: 75) a temporary buffer rather than a sign of financial…
The first sentence of the analysis written for OLMA on 2026-07-29 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 9.950 | 10.500 | 12.327 | 12.623 | 32.230 | |
| Quick Ratio | 9.950 | 10.500 | 12.327 | 12.623 | 32.230 | |
| Solvency Ratio | -2.952 | -3.072 | -4.177 | -5.770 | -6.235 | |
| Cash Ratio | 0.932 | 3.340 | 3.170 | 1.432 | 1.531 | |
| Price To Earnings Ratio | -13.369 | -2.650 | -6.556 | -0.935 | -5.229 | |
| Price To Earnings Growth Ratio | 0.891 | -0.945 | 0.358 | -0.020 | -0.025 | |
| Forward Price To Earnings Growth Ratio | 0.891 | -0.945 | 0.358 | -0.020 | -0.025 | |
| Price To Book Ratio | 4.545 | 0.837 | 2.500 | 0.496 | 1.300 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -14.826 | -3.277 | -7.582 | -1.189 | -7.078 | |
| Price To Operating Cash Flow Ratio | -14.826 | -3.282 | -7.582 | -1.194 | -7.298 | |
| Debt To Assets Ratio | 0.002 | 0.003 | 0.009 | 0.012 | 0.011 | |
| Debt To Equity Ratio | 0.002 | 0.003 | 0.010 | 0.013 | 0.012 | |
| Debt To Capital Ratio | 0.002 | 0.003 | 0.009 | 0.013 | 0.011 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.115 | 1.103 | 1.091 | 1.092 | 1.040 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -2.832 | -2.499 | -3.872 | -4.959 | -5.620 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.002 | 1.000 | 1.004 | 1.031 | |
| Debt Service Coverage Ratio | -144.093 | -110.137 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -130.530 | -89.037 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -122.981 | -73.024 | -34.641 | -31.994 | -15.412 | |
| Capital Expenditure Coverage Ratio | 0.000 | -656.296 | 0.000 | -226.074 | -32.184 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | -656.296 | 0.000 | -226.074 | -32.184 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -13.139 | -1.584 | -5.907 | -0.736 | -5.067 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 9.950 | ▼-0.550 | ▼-5.576 |
| Quick Ratio | 9.950 | ▼-0.550 | ▼-5.576 |
| Solvency Ratio | -2.952 | ▲0.121 | ▲1.489 |
| Cash Ratio | 0.932 | ▼-2.408 | ▼-1.149 |
| Price To Earnings Ratio | -13.369 | ▼-10.719 | ▼-7.621 |
| Price To Earnings Growth Ratio | 0.891 | ▲1.836 | ▲0.840 |
| Forward Price To Earnings Growth Ratio | 0.891 | ▲1.836 | ▲0.840 |
| Price To Book Ratio | 4.545 | ▲3.708 | ▲2.609 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -14.826 | ▼-11.549 | ▼-8.035 |
| Price To Operating Cash Flow Ratio | -14.826 | ▼-11.544 | ▼-7.989 |
| Debt To Assets Ratio | 0.002 | ▼-0.001 | ▼-0.005 |
| Debt To Equity Ratio | 0.003 | ▼-0.001 | ▼-0.005 |
| Debt To Capital Ratio | 0.003 | ▼-0.001 | ▼-0.005 |
| Long Term Debt To Capital Ratio | 0.000 | ▲0.000 | ▲0.000 |
| Financial Leverage Ratio | 1.115 | ▲0.012 | ▲0.027 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -2.832 | ▼-0.333 | ▲1.124 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | ▼-0.002 | ▼-0.007 |
| Debt Service Coverage Ratio | -144.093 | ▼-33.956 | ▼-93.247 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | -130.530 | ▼-41.494 | ▼-86.617 |
| Operating Cash Flow Coverage Ratio | -122.981 | ▼-49.957 | ▼-67.370 |
| Capital Expenditure Coverage Ratio | 0.000 | ▲656.296 | ▲182.911 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | ▲656.296 | ▲182.911 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -13.139 | ▼-11.556 | ▼-7.853 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $2.18B | $342.5M | $634.8M | $98.0M | $369.9M | |
| Enterprise value | $2.13B | $204.4M | $568.7M | $76.9M | $359.4M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -14.51x | -1.96x | -6.79x | -0.94x | -7.09x | |
| EV / Free cash flow | -14.51x | -1.96x | -6.79x | -0.93x | -6.88x | |
| EV / EBITDA | -13.14x | -1.58x | -5.91x | -0.74x | -5.07x | |
| Net debt / EBITDA | 0.29x | 1.07x | 0.69x | 0.20x | 0.15x | |
| Current ratio | 9.95x | 10.50x | 12.33x | 12.62x | 32.23x | |
| Income quality | 0.90x | 0.81x | 0.87x | 0.78x | 0.71x | |
| Graham net-net | $5 | $7 | $5 | $5 | $7 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $463.6M | $396.7M | $244.9M | $192.3M | $281.7M | |
| Invested capital | $464.8M | $399.5M | $248.2M | $196.3M | $286.4M | |
| Return on assets | -30.5% | -28.7% | -34.9% | -48.6% | -24.0% | |
| Operating ROA | -36.3% | -39.1% | -42.6% | -41.8% | -22.4% | |
| Return on tangible assets | -30.5% | -28.8% | -34.9% | -48.6% | -24.0% | |
| Return on equity | -33.9% | -31.7% | -38.1% | -53.0% | -25.0% | |
| Return on invested capital | -37.0% | -34.7% | -41.0% | -53.5% | -24.8% | |
| Return on capital employed | -37.1% | -34.8% | -41.1% | -53.7% | -24.9% | |
| Earnings yield | -7.5% | -37.8% | -15.2% | -106.9% | -19.2% | |
| Free cash flow yield | -6.7% | -30.5% | -13.2% | -84.1% | -14.1% | |
| Capex / Op. cash flow | 0.0% | -0.2% | 0.0% | -0.4% | -3.1% | |
| Capex / Depreciation | 0.0% | 40.5% | 0.0% | 21.9% | 94.7% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.2% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+535.1%EV / Sales n/aEV / EBITDA ▼-729.7%EV / Op. cash flow ▼-12.546Earnings yield ▲+0.303
Profitability
Return on equity ▼-0.023Return on assets ▼-0.017Return on invested capital ▼-0.024Return on capital employed ▼-0.023Operating ROA ▲+0.028Income quality ▲+0.097Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.550Net debt / EBITDA ▼-0.779Working capital ▲+66935000.000Invested capital ▲+65338000.000Intangibles / Total assets ▼-0.002
Change over 5 years
Valuation
Market cap ▲+488.0%EV / Sales n/aEV / EBITDA ▼-159.3%EV / Op. cash flow ▼-7.414Earnings yield ▲+0.117
Profitability
Return on equity ▼-0.090Return on assets ▼-0.064Return on invested capital ▼-0.122Return on capital employed ▼-0.122Operating ROA ▼-0.139Income quality ▲+0.190Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-22.280Net debt / EBITDA ▲+0.143Working capital ▲+181984000.000Invested capital ▲+178410000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-06-09 Olema Pharmaceuticals, Inc. (OLMA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript Olema Pharmaceuticals, Inc. (OLMA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
- 2026-06-02 Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, June 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to six new employees to purchase an aggregate of 176,150 shares of the Company's common stock, effective as of June 1, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
- 2026-05-26 Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer Study to evaluate OP-3136, Olema's novel KAT6 inhibitor, in combination with darolutamide in approximately 36 patients; expected to initiate in H2 2026 First clinical collaboration for OP-3136; results to inform combination strategy in metastatic prostate cancer setting SAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced a clinical trial collaboration and supply agreement with Bayer AG (“Bayer”) to evaluate OP-3136, Olema's investigational lysine acetyltransferase 6 (KAT6) inhibitor, in combination with NUBEQA® (darolutamide), Bayer's androgen receptor inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC). The Phase 1b/2 study is designed to assess the safety, tolerability, and preliminary anti-tumor activity of OP-3136 in combination with darolutamide in approximately 36 patients with mCRPC.
- 2026-05-21 Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting OP-3136 monotherapy was well-tolerated with no dose-limiting toxicities observed and no discontinuations due to treatment-related adverse events OP-3136 shows evidence of anti-tumor activity across multiple solid tumor types Data support the ongoing Phase 1 evaluation of OP-3136 as a monotherapy and in combination with fulvestrant and palazestrant SAN FRANCISCO, May 21, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced preliminary clinical data from the Phase 1 study of OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor. The data will be presented in a poster presentation on May 30, 2026 at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois.
- 2026-05-19 Olema Oncology to Participate in Upcoming Investor Conferences SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences: TD Cowen 7 th Annual Oncology Innovation Summit Date and Time: May 26, 2026 at 12:30 p.m. ETFormat: Fireside ChatLocation: Virtual Jefferies Global Healthcare Conference Date and Time: June 3, 2026 at 8:45 a.m.
- 2026-05-04 Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to five new employees to purchase an aggregate of 154,700 shares of the Company's common stock, effective as of May 1, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
- 2026-04-29 Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors SAN FRANCISCO, April 29, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the appointment of Prakash Raman, Ph.D., to its Board of Directors.